A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

The ITC found that "multiple bad actors" have been importing or selling knockoff copies of Lilly's tirzepatide.

The lawsuit was brought against the FDA after the agency declared an end to the shortage that allowed pharmacies to sell compound versions of the popular weight loss drugs, but Eli Lilly said it ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

The state has spent more than $690 million so far establishing the LEAP Research and Innovation District. Outgoing economic ...